Form 4: Vivos Therapeutics CFO Acquires Stock Options Following Shareholder Approval

Vivos Therapeutics' Chief Financial Officer, Bradford K. Amman, acquired 149,533 stock options after shareholder approval of the 2024 Omnibus Equity Incentive Plan.

Summary

• Bradford K. Amman, the Chief Financial Officer of Vivos Therapeutics, Inc., reported a transaction involving stock options.
• On November 26, 2024, Amman acquired 149,533 stock options at an exercise price of $2.64 per share.
• These options are part of a grant of 180,533 stock options made on September 7, 2024, which was subject to shareholder approval.
• The shareholder approval was obtained at the company's 2024 Annual Meeting on November 26, 2024.
• The stock options vest in three installments based on performance metrics including revenue growth, total shareholder return, and positive cash flow.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, with positive implications for aligning management and shareholder interests. The vesting conditions add a layer of positive sentiment as they are tied to performance.

Positives

• The acquisition of stock options by the CFO aligns his interests with those of the shareholders.
• The vesting of the options is tied to performance metrics, which could incentivize the CFO to drive company growth and profitability.
• Shareholder approval of the equity incentive plan indicates support for management's compensation strategy.

Risks

• The vesting of the stock options is contingent on achieving specific performance metrics, which may not be met.
• The value of the stock options is dependent on the future performance of the company's stock price.

Future Outlook

The vesting of the stock options is dependent on the company achieving specific performance metrics, including revenue growth, total shareholder return, and positive cash flow.

Industry Context

This type of stock option grant is a common practice in the industry to align management's interests with those of the shareholders and incentivize performance.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for executives in publicly traded companies, particularly in the biotech and healthcare sectors.
• The vesting conditions tied to performance metrics are also common, aligning executive compensation with company performance and shareholder value creation.
• Companies like Align Technology and InMode also use stock options as part of their executive compensation packages, often with similar performance-based vesting schedules.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns management's interests with their own.
• Employees may be motivated by the company's focus on performance-based compensation.

Key Dates

Keywords

stock options, equity incentive plan, shareholder approval, CFO, Vivos Therapeutics, performance metrics, insider trading